StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Trevena Stock Up 5.3 %
Shares of TRVN opened at $3.94 on Friday. Trevena has a 52-week low of $3.35 and a 52-week high of $19.23. The stock has a market cap of $3.35 million, a PE ratio of -1.47 and a beta of 1.03. The firm’s fifty day moving average is $3.15 and its two-hundred day moving average is $1.35.
Trevena (NASDAQ:TRVN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.36. The business had revenue of $0.33 million for the quarter. As a group, research analysts anticipate that Trevena will post -32.25 earnings per share for the current year.
Institutional Inflows and Outflows
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Articles
- Five stocks we like better than Trevena
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Learn Technical Analysis Skills to Master the Stock Market
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is a Death Cross in Stocks?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.